Aberrant, ectopic expression of VEGF and VEGF receptors 1 and 2 in malignant colonic epithelial cells. Implications for these cells growth via an autocrine mechanism

Biochemical and Biophysical Research Communications

Volumn 437, Issue 4, 2013, Pages 515-520

  Ahluwalia, Amrita ^a   Jones, Michael K ^a,b   Szabo, Sandor ^a,c   Tarnawski, Andrzej S ^a,b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cell growth; Colon cancer; VEGF; VEGF receptors

Indexed keywords

MESSENGER RNA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL GROWTH; CELL PROLIFERATION; COLON; COLON ADENOCARCINOMA; COLON CANCER; COLONIC EPITHELIAL CELL; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY;

°C; ΜL; ΜM; CELL GROWTH; COLON CANCER; COLON CANCER CELL LINE; COLORECTAL CANCER; CRC; DEGREES CENTIGRADE; H; HCT116; HOURS; HT29; MESSENGER RIBONUCLEIC ACID; MICRO LITER; MICRO MOLAR; MILLIMETER; MILLIMOLAR; MM; MRNA; NANOMETER; NCM356; NCM460; NM; NORMAL COLONIC MUCOSAL EPITHELIAL CELLS; REVERSE TRANSCRIPTION AND POLYMERASE CHAIN REACTION; RT-PCR; VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2; VEGF; VEGF RECEPTORS; VEGF-R1; VEGF-R2;

CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84881547592     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.06.096     Document Type: Article

References (36)

1. Folkman J., D'Amore P.A. Blood vessel formation: what is its molecular basis?. Cell 1996, 87:1153-1155.
2. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936.
3. Ferrara N., Henzel W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 1989, 161:851-858.
4. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
5. Ferrara N. VEGF-A: a critical regulator of blood vessel growth. Eur. Cytokine Netw. 2009, 20:158-163.
6. Ferrara N. Vascular endothelial growth factor. Arterioscler. Thromb. Vasc. Biol. 2009, 29:789-791.
7. Ellis L.M., Takahashi Y., Liu W., Shaheen R.M. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist 2000, 5(Suppl. 1):11-15.
8. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005, 69(Suppl. 3):11-16.
9. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 2005, 209-231.
10. Deng X., Szabo S., Khomenko T., Jadus M.R., Yoshida M. Gene therapy with adenoviral plasmids or naked DNA of vascular endothelial growth factor and platelet-derived growth factor accelerates healing of duodenal ulcer in rats. J Pharmacol Exp Ther. 2004, 311:982-988.
11. Adams J., Carder P.J., Downey S., Forbes M.A., MacLennan K., Allgar V., Kaufman S., Hallam S., Bicknell R., Walker J.J., Cairnduff F., Selby P.J., Perren T.J., Lansdown M., Banks R.E. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res. 2000, 60:2898-2905.
12. Gasparini G., Toi M., Gion M., Verderio P., Dittadi R., Hanatani M., Matsubara I., Vinante O., Bonoldi E., Boracchi P., Gatti C., Suzuki H., Tominaga T. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J. Natl. Cancer Inst. 1997, 89:139-147.
13. Duncan T.J., Al Attar A., Rolland P., Scott I.V., Deen S., Liu D.T., Spendlove I., Durrant L.G. Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?. Clin. Cancer Res. 2008, 14:3030-3035.
14. Ishigami S.I., Arii S., Furutani M., Niwano M., Harada T., Mizumoto M., Mori A., Onodera H., Imamura M. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br. J. Cancer. 1998, 78:1379-1384.
15. Zhang Y., Liu X., Zhang J., Li L., Liu C. The expression and clinical significance of PI3K, pAkt and VEGF in colon cancer. Oncol. Lett. 2012, 4:763-766.
16. Huang C., Huang R., Chang W., Jiang T., Huang K., Cao J., Sun X., Qiu Z. The expression and clinical significance of pSTAT3, VEGF and VEGF-C in pancreatic adenocarcinoma. Neoplasma 2012, 59:52-61.
17. Kozłowski M., Laudański W., Mroczko B., Szmitkowski M., Milewski R., Lapuć G. Serum tissue inhibitor of metalloproteinase 1 (TIMP-1) and vascular endothelial growth factor A (VEGF-A) are associated with prognosis in esophageal cancer patients. Adv Med Sci. 2013, 18:1-8.
18. Kondo Y., Arii S., Mori A., Furutani M., Chiba T., Imamura M. Enhancement of angiogenesis, tumor growth, and metastasis by transfection of vascular endothelial growth factor into LoVo human colon cancer cell line. Clin. Cancer Res. 2000, 6:622-630.
19. Yuan F., Chen Y., Dellian M., Safabakhsh N., Ferrara N., Jain R.K. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:14765-14770.
20. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350:2335-2342.
21. Khorana A.A., Ryan C.K., Cox C., Eberly S., Sahasrabudhe D.M. Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis. Cancer 2003, 97:960-968.
22. Harada Y., Ogata Y., Shirouzu K. Expression of vascular endothelial growth factor and its receptor KDR (kinase domain-containing receptor)/Flk-1 (fetal liver kinase-1) as prognostic factors in human colorectal cancer. Int. J. Clin. Oncol. 2001, 6:221-228.
23. Warren R.S., Yuan H., Matli M.R., Gillett N.A., Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. 1995, 95:1789-1797.
24. Calvani M., Trisciuoglio D., Bergamaschi C., Shoemaker R.H., Melillo G. Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells. Cancer Res. 2008, 68:285-291.
25. Coron E., Mosnier J.F., Ahluwalia A., Le Rhun M., Galmiche J.P., Tarnawski A.S., Matysiak-Budnik T. Colonic mucosal biopsies obtained during confocal endomicroscopy are pre-stained with fluorescein in vivo and are suitable for histologic evaluation. Endoscopy 2012, 44:148-153.
26. Ahluwalia A., Narula J., Jones M.K., Deng X., Tarnawski A.S. Impaired angiogenesis in aging myocardial microvascular endothelial cells is associated with reduced importin alpha and decreased nuclear transport of HIF1 alpha: mechanistic implications. J. Physiol. Pharmacol. 2010, 61:133-139.
27. Tarnawski A., Pai R., Deng X., Ahluwalia A., Khomenko T., Tanigawa T., Akahoshi T., Sandor Z., Szabo S. Aging gastropathy-novel mechanisms: hypoxia, up-regulation of multifunctional phosphatase PTEN, and proapoptotic factors. Gastroenterology 2007, 133:1938-1947.
28. Ahluwalia A., Clodfelter K.H., Waxman D.J. Sexual dimorphism of rat liver gene expression: regulatory role of growth hormone revealed by deoxyribonucleic acid microarray analysis. Mol. Endocrinol. 2004, 18:747-760.
29. Jones M.K., Wang H., Peskar B.M., Levin E., Itani R.M., Sarfeh I.J., Tarnawski A.S. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med. 1999, 5:1418-1423.
30. Manley P.W., Furet P., Bold G., Bruggen J., Mestan J., Meyer T., Schnell C.R., Wood J., Haberey M., Huth A., Kruger M., Menrad A., Ottow E., Seidelmann D., Siemeister G., Thierauch K.H. Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J. Med. Chem. 2002, 45:5687-5693.
31. Yamaguchi R., Yano H., Iemura A., Ogasawara S., Haramaki M., Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 1998, 28:68-77.
32. Shi B., Wang X., Yang Z. Vascular endothelial growth factors and liver diseases. Hepatogastroenterology 2001, 48:1145-1148.
33. Foersch S., Kiesslich R., Waldner M.J., Delaney P., Galle P.R., Neurath M.F., Goetz M. Molecular imaging of VEGF in gastrointestinal cancer in vivo using confocal laser endomicroscopy. Gut 2010, 59:1046-1055.
34. Fan F., Wey J.S., McCarty M.F., Belcheva A., Liu W., Bauer T.W., Somcio R.J., Wu Y., Hooper A., Hicklin D.J., Ellis L.M. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 2005, 24:2647-2653.
35. Takahashi Y., Kitadai Y., Bucana C.D., Cleary K.R., Ellis L.M. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995, 55:3964-3968.
36. Schmoll H.J., Cunningham D., Sobrero A., Karapetis C.S., Rougier P., Koski S.L., Kocakova I., Bondarenko I., Bodoky G., Mainwaring P., Salazar R., Barker P., Mookerjee B., Robertson J., Van Cutsem E. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J. Clin. Oncol. 2012, 30:3588-3595.